Devonian Health Group Inc. Reports Superior Anti-Inflammatory Potency of Thykamine™ in Comparative In Vitro Study
Devonian Health Group announced results from an in vitro comparative study showing Thykamine™ demonstrated superior anti-inflammatory potency compared to current market alternatives. The study, conducted at Université Laval, compared Thykamine™ against various corticosteroids and a phosphodiesterase inhibitor.
The study measured the inhibition of four cytokines (MCP-1, MIP-1α, MIP-1β and RANTES) in LPS-stimulated U937 monocytic cells. Thykamine™ showed significantly higher inhibition potency for MCP-1 (28-136%), MIP-Alpha (30-108%), MIP-1 Beta (39-111%), and RANTES (47-258%, except versus Crisaborole and Prednisone). The results support Thykamine™'s wide-spectrum anti-inflammatory properties and multi-mode action, complementing its previous clinical efficacy in phase 2 studies for ulcerative colitis and atopic dermatitis.
Devonian Health Group ha annunciato i risultati di uno studio comparativo in vitro che dimostra come Thykamine™ abbia mostrato una potenza anti-infiammatoria superiore rispetto alle attuali alternative di mercato. Lo studio, condotto presso l'Université Laval, ha confrontato Thykamine™ con vari corticosteroidi e un inibitore della fosfodiesterasi.
Lo studio ha misurato l'inibizione di quattro citochine (MCP-1, MIP-1α, MIP-1β e RANTES) in cellule monocitiche U937 stimolate da LPS. Thykamine™ ha mostrato una potenza di inibizione significativamente più alta per MCP-1 (28-136%), MIP-Alfa (30-108%), MIP-1 Beta (39-111%) e RANTES (47-258%, eccetto rispetto a Crisaborolo e Prednisone). I risultati supportano le proprietà anti-infiammatorie ad ampio spettro di Thykamine™ e la sua azione multimodale, complementando la sua efficacia clinica precedente negli studi di fase 2 per la colite ulcerosa e la dermatite atopica.
Devonian Health Group ha anunciado los resultados de un estudio comparativo in vitro que muestra cómo Thykamine™ demostró una potencia antiinflamatoria superior en comparación con las alternativas actuales del mercado. El estudio, realizado en la Université Laval, comparó Thykamine™ con varios corticosteroides y un inhibidor de la fosfodiesterasa.
El estudio midió la inhibición de cuatro citoquinas (MCP-1, MIP-1α, MIP-1β y RANTES) en células monocíticas U937 estimuladas por LPS. Thykamine™ mostró una potencia de inhibición significativamente más alta para MCP-1 (28-136%), MIP-Alfa (30-108%), MIP-1 Beta (39-111%) y RANTES (47-258%, excepto en comparación con Crisaborole y Prednisona). Los resultados apoyan las propiedades antiinflamatorias de amplio espectro de Thykamine™ y su acción multimodal, complementando su eficacia clínica previa en estudios de fase 2 para colitis ulcerosa y dermatitis atópica.
Devonian Health Group는 Thykamine™이 현재 시장 대안과 비교하여 우수한 항염증 효능을 나타냈다는 분석 결과를 발표했습니다. 이 연구는 Université Laval에서 수행되었으며, Thykamine™을 여러 종류의 코르티코스테로이드 및 포스포디에스터라제 억제제와 비교했습니다.
연구는 LPS에 의해 자극된 U937 단핵구 세포에서 네 가지 사이토카인(MCP-1, MIP-1α, MIP-1β 및 RANTES)의 억제를 측정했습니다. Thykamine™은 MCP-1(28-136%), MIP-알파(30-108%), MIP-1 베타(39-111%) 및 RANTES(47-258%, Crisaborole 및 Prednisone 제외)에 대해 유의미하게 높은 억제력을 보였습니다. 이 결과는 Thykamine™의 광범위한 항염증 특성과 다중 방식 작용을 뒷받침하며, 이전의 임상 2상 연구에서 궤양성 대장염 및 아토피 피부염에 대한 효능과 상호 보완적입니다.
Devonian Health Group a annoncé les résultats d'une étude comparative in vitro montrant que Thykamine™ demonstré une puissance anti-inflammatoire supérieure par rapport aux alternatives actuellement sur le marché. L'étude, réalisée à l'Université Laval, a comparé Thykamine™ avec divers corticostéroïdes et un inhibiteur de la phosphodiestérase.
L'étude a mesuré l'inhibition de quatre cytokines (MCP-1, MIP-1α, MIP-1β et RANTES) dans des cellules monocytaires U937 stimulées par le LPS. Thykamine™ a montré une puissance d'inhibition significativement plus élevée pour MCP-1 (28-136%), MIP-alpha (30-108%), MIP-1 Beta (39-111%) et RANTES (47-258%, sauf par rapport à Crisaborole et Prednisone). Les résultats soutiennent les propriétés anti-inflammatoires à large spectre de Thykamine™ et son action multi-mode, complétant son efficacité clinique antérieure dans les études de phase 2 pour la colite ulcéreuse et la dermatitis atopique.
Devonian Health Group hat die Ergebnisse einer in vitro Vergleichsstudie veröffentlicht, aus der hervorgeht, dass Thykamine™ eine überlegene entzündungshemmende Wirksamkeit im Vergleich zu aktuellen Marktalternativen gezeigt hat. Die Studie, die an der Université Laval durchgeführt wurde, verglich Thykamine™ mit verschiedenen Kortikosteroiden und einem Phosphodiesterasehemmer.
In der Studie wurde die Hemmung von vier Zytokinen (MCP-1, MIP-1α, MIP-1β und RANTES) in LPS-stimulierten U937-Monozyten gemessen. Thykamine™ zeigte eine signifikant höhere Hemmungswirksamkeit für MCP-1 (28-136%), MIP-Alph (30-108%), MIP-1 Beta (39-111%) und RANTES (47-258%, außer im Vergleich mit Crisaborol und Prednison). Die Ergebnisse unterstützen die breiten entzündungshemmenden Eigenschaften von Thykamine™ und ihre multimodale Wirkung und ergänzen die vorherige klinische Wirksamkeit in Phase-2-Studien zur Colitis ulcerosa und atopischen Dermatitis.
- Thykamine™ demonstrated superior anti-inflammatory potency versus current market treatments
- Showed significantly higher inhibition across multiple cytokines (28-258% improvement)
- Results support previous positive Phase 2 clinical efficacy data
- Favorable safety profile positions it as potential first-line treatment
- None.
- In vitro study demonstrated superior potency of Thykamine™ against various corticosteroids and a phosphodiesterase inhibitor
- Supports the clinical efficacy results of Thykamine™ in previous and ongoing studies in the treatment of various autoimmune inflammatory diseases
The primary objective of the study was to compare the anti-inflammatory potency of Thykamine™ to other anti-inflammatory agents in the market, specifically betamethasone valerate, clobetasol, crisaborole, 21-acetate hydrocortisone, pimecrolimus and prednisone. The experiment involved treating lipopolysaccharide (LPS) stimulated U937 monocytic cells with each agent. Anti-inflammatory potency was assessed by the percent inhibition of the activity of four cytokines induced by each agent. The four cytokines tested were MCP-1, MIP-1α, MIP-1β and RANTES that have been implicated in several autoimmune diseases. Percent inhibition was calculated as the reduction in lipopolysaccharide (LPS) induced cytokine activity after addition of the agent. Given that the aim of anti-inflammatory drugs is to dampen cytokine induced inflammation, these results can be used as inference to overall anti-inflammatory efficacy.
All agents were tested at four increasing concentrations except for pimecrolimus that was tested at three concentrations. All culture conditions were run in hexaplicate (n=6). Cell-free supernatants were collected and immediately assayed for cytokine concentration using Pro-Carta 6 plex (Life Technologies). U937 secreted amounts of IL-6 or IL-10 that were below the detection limits of the assay and were not included in the analyses.
When compared to the other agents, Thykamine™ showed clinically important and statistically significant higher inhibition potency for MCP-1 (by
“These results support the wide spectrum anti-inflammatory properties of Thykamine™ with potency that is superior to currently marketed anti-inflammatory agents. This study indicates a multi mode of action of Thykamine™ affecting several cytokines and other biomarkers, supporting the clinical efficacy demonstrated in phase 2 studies in ulcerative colitis and atopic dermatitis in adults,” said Dr Louis Flamand, lead study investigator.
“The high potency and previously established clinical efficacy of Thykamine™ , combined with its placebo-like safety, should compel practitioners to consider its use as a first line treatment, especially with the potential safety concerns of the present standard of care,” said Dr Lynde, who was consulted on the current study and was the lead investigator in Devonian’s phase 2 study in adults with mild-to-moderate atopic dermatitis.
The study’s co-investigator Dr. John Sampalis, Clinical Epidemiologist, and Professor of Medicine at McGill with extensive experience in the evaluation of treatments for autoimmune disorders commented: “The results of this in vitro study are extremely encouraging. The favorable safety profile of Thykamine™ as demonstrated in human clinical studies and its high anti-inflammatory potency proven in this study, would position Thykamine™ as a possible first line treatment of choice for several autoimmune conditions in the early stages of the disease. This can result in steroid sparing effect and reduced need for aggressive treatments with biologics and other immune modulators, that are associated with serious side effects and long term negative consequences.”
Investigators of this study are planning to submit the results in a peer-reviewed journal.
(1) Pr. Louis Flamand is a director on the board of directors of the Corporation |
About Thykamine™
Thykamine™, the first pharmaceutical product issued from Devonian’s SUPREX™ platform, is a highly innovative product for the prevention and treatment of health conditions related to inflammation and oxidative stress including ulcerative colitis, atopic dermatitis, psoriasis, rheumatoid arthritis, and other autoimmune disorders. The anti-inflammatory, anti-oxidative and immunomodulatory properties of Thykamine™ have been demonstrated by a considerable number of in vitro and in vivo studies as well as in a Phase IIa clinical study in patients with mild-to-moderate distal ulcerative colitis and in a large phase II study in adult patients with mild-to-moderate Atopic Dermatitis. Both Thykamine™ and SUPREX™ platform are protected by several patents in
About Devonian
Devonian Health Group Inc. is a clinical stage pharmaceutical company specializing in the development of drugs for various auto-immune inflammatory conditions with novel therapeutic approaches to targeting unmet medical needs. Devonian’s core strategy is to develop prescription drugs for the treatment of inflammatory autoimmune diseases including but not limited to ulcerative colitis and atopic dermatitis. Based on a foundation of over 15 years of research, Devonian’s focus is further supported by a
Devonian is also involved in the development of high-value cosmeceutical products leveraging the same proprietary approach employed with their pharmaceutical offerings. Devonian also owns a commercialization subsidiary, Altius Healthcare Inc., focused on selling prescription pharmaceutical products in
Devonian Health Group Inc. was incorporated in 2015 and is headquartered in
For more information, visit www.groupedevonian.com
Cautionary Note Regarding Forward-Looking Statements
All statements, other than statements of historical fact, contained in this press release including but, not limited to those relating to the economical impact of clinical study, the efficiency of the high anti-inflammatory potency proven and the position of the Thykamine™ as a possible first line treatment of choice for several autoimmune conditions in the early stages of the disease and the reduced need for aggressive treatments with biologics and other immune modulators, that are associated with serious side effects and long term negative consequences, and, generally, the above “About Devonian” and “About Altius” paragraphs, which essentially describes the Corporation’s outlook, constitute “forward-looking information” or “forward-looking statements” within the meaning of certain securities laws, and are based on expectations, estimates and projections as of the time of this press release.
Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by the Corporation as of the time of such statements, are inherently subject to significant business, economic and competitive uncertainties and contingencies. These estimates and assumptions may prove to be incorrect. Many of these uncertainties and contingencies can directly or indirectly affect, and could cause, actual results to differ materially from those expressed or implied in any forward-looking statements. There can be no assurance that these assumptions will prove to be correct and there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.
By their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific, and risks exist that estimates, forecasts, projections and other forward-looking statements will not be achieved or that assumptions do not reflect future experience. Forward-looking statements are provided for the purpose of providing information about management’s expectations and plans relating to the future. Readers are cautioned not to place undue reliance on these forward-looking statements as a number of important risk factors and future events could cause the actual outcomes to differ materially from the beliefs, plans, objectives, expectations, anticipations, estimates, assumptions and intentions expressed in such forward-looking statements. All of the forward-looking statements made in this press release are qualified by these cautionary statements and those made in our other filings with the applicable securities regulators of
Neither the Exchange nor its Regulation Services Provider (as that term is defined in policies of the Exchange) accepts responsibility for the adequacy or accuracy of this release.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250204710687/en/
Devonian Health Group Inc.
Mr. Luc Gregoire
President & CEO
Dr. Andre P. Boulet, PhD
Chairman, Chief Scientific Officer and Chief Operating Officer
Telephone: 1 (450) 979-2916
E-mail: investors@groupedevonian.com
Renmark Financial Communications Inc.
Mr. Ben Ozerkevich
Telephone: (416) 644-2020 or (212) 812-7680
E-mail: bozerkevich@renmarkfinancial.com
www.renmarkfinancial.com
Source: Devonian Health Group Inc.
FAQ
What were the key findings of DVHGF's Thykamine™ comparative study?
How does Thykamine™ compare to existing corticosteroids in inflammation control?
What medical conditions could Thykamine™ (DVHGF) potentially treat?
What advantages does Thykamine™ offer over current inflammatory treatments?
